<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39954732</PMID><DateCompleted><Year>2025</Year><Month>04</Month><Day>18</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2341-1929</ISSN><JournalIssue CitedMedium="Internet"><Volume>72</Volume><Issue>4</Issue><PubDate><Year>2025</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Revista espanola de anestesiologia y reanimacion</Title><ISOAbbreviation>Rev Esp Anestesiol Reanim (Engl Ed)</ISOAbbreviation></Journal><ArticleTitle>Utility of optic nerve sheath ultrasound during laparoscopic colorectal surgery.</ArticleTitle><Pagination><StartPage>501672</StartPage><MedlinePgn>501672</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.redare.2025.501672</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2341-1929(25)00043-5</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Abdominal laparoscopic surgery to treat colorectal cancer has been shown to be more effective than open surgery in terms of mobility, hospital stay, tumour recurrence and long-term survival. This surgical approach requires pneumoperitoneum and the Trendelenburg position (35-45&#xba;), both of which have a negative effect on the cardiovascular system and can even change the cerebrovascular physiology, leading to an increase in intracranial pressure (ICP). Ultrasound measurement of optic nerve sheath (ONS) diameter has shown excellent correlation with invasive ICP measurement.</AbstractText><AbstractText Label="OBJECTIVE">To correlate the increase in ONS diameter with surgical time and time to emergence after anaesthesia. The incidence of visual disturbances (visual acuity) and/or neurological complications (agitation, cognitive dysfunction) in the immediate postoperative period was also evaluated.</AbstractText><AbstractText Label="MATERIAL AND METHODS">30 consecutive patients undergoing laparoscopic surgery for rectal or sigmoid adenocarcinoma were recruited. Pre-, intra- and postoperative ONS measurements were obtained and the Snellen test for visual acuity, Mini Mental Test for cognitive function, and the Richmond Agitation and Sedation Scale (RASS) were administered.</AbstractText><AbstractText Label="RESULTS">ONS increased intraoperatively in both eyes compared to baseline. However, this was not correlated with total surgical time or time to emergence, and there was no statistically significant correlation between ONS and postoperative neurological or visual alterations.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 Sociedad Espa&#xf1;ola de Anestesiolog&#xed;a, Reanimaci&#xf3;n y Terap&#xe9;utica del Dolor. Publicado por Elsevier Espa&#xf1;a, S.L.U. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Alcover Navarro</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Servicio de Anestesiolog&#xed;a, Reanimaci&#xf3;n y Tratamiento del Dolor, Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain. Electronic address: alcover.laura@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Romero Garc&#xed;a</LastName><ForeName>C S</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>Servicio de Anestesiolog&#xed;a, Reanimaci&#xf3;n y Tratamiento del Dolor, Hospital General Universitario de Valencia, Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mateo Rodr&#xed;guez</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Servicio de Anestesiolog&#xed;a, Reanimaci&#xf3;n y Tratamiento del Dolor, Hospital General Universitario de Valencia, Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Granero Castro</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Servicio de Cirug&#xed;a General y del Aparato Digestivo, Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Andr&#xe9;s Ib&#xe1;&#xf1;ez</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Servicio de Anestesiolog&#xed;a, Reanimaci&#xf3;n y Tratamiento del Dolor, Hospital General Universitario de Valencia, Valencia, Spain; Universidad de Valencia, Valencia, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>02</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Rev Esp Anestesiol Reanim (Engl Ed)</MedlineTA><NlmUniqueID>101778594</NlmUniqueID><ISSNLinking>2341-1929</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010535" MajorTopicYN="Y">Laparoscopy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009900" MajorTopicYN="Y">Optic Nerve</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014463" MajorTopicYN="N">Ultrasonography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000230" MajorTopicYN="Y">Adenocarcinoma</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061646" MajorTopicYN="N">Operative Time</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012004" MajorTopicYN="Y">Rectal Neoplasms</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012811" MajorTopicYN="Y">Sigmoid Neoplasms</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018475" MajorTopicYN="N">Head-Down Tilt</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016343" MajorTopicYN="Y">Monitoring, Intraoperative</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alteraciones visuales postoperatorias</Keyword><Keyword MajorTopicYN="N">Disfunci&#xf3;n cognitiva postoperatoria</Keyword><Keyword MajorTopicYN="N">Di&#xe1;metro vaina nervio &#xf3;ptico</Keyword><Keyword MajorTopicYN="N">Ecograf&#xed;a ocular</Keyword><Keyword MajorTopicYN="N">Hipertensi&#xf3;n intracraneal</Keyword><Keyword MajorTopicYN="N">Intracranial hypertension</Keyword><Keyword MajorTopicYN="N">Ocular ultrasound</Keyword><Keyword MajorTopicYN="N">Optic nerve sheath diameter</Keyword><Keyword MajorTopicYN="N">Postoperative cognitive dysfunction</Keyword><Keyword MajorTopicYN="N">Postoperative visual disturbances</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors have no conflict of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>4</Month><Day>19</Day><Hour>0</Hour><Minute>56</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>2</Month><Day>16</Day><Hour>1</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>2</Month><Day>15</Day><Hour>19</Hour><Minute>29</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39954732</ArticleId><ArticleId IdType="doi">10.1016/j.redare.2025.501672</ArticleId><ArticleId IdType="pii">S2341-1929(25)00043-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39079135</PMID><DateCompleted><Year>2024</Year><Month>07</Month><Day>30</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2590-7379</ISSN><JournalIssue CitedMedium="Internet"><Volume>44</Volume><Issue>Sp. 1</Issue><PubDate><Year>2024</Year><Month>May</Month><Day>31</Day></PubDate></JournalIssue><Title>Biomedica : revista del Instituto Nacional de Salud</Title><ISOAbbreviation>Biomedica</ISOAbbreviation></Journal><ArticleTitle>Pheochromocytoma/paraganglioma type 5 syndrome as a cause of secondary hypertension in a Colombian patient: case report.</ArticleTitle><Pagination><StartPage>18</StartPage><EndPage>26</EndPage><MedlinePgn>18-26</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.7705/biomedica.7152</ELocationID><Abstract><AbstractText>Pheochromocytoma is a tumor derived from neural crest cells able to produce sympathomimetic substances and, hence, a particular clinical picture. It is responsible for less than 1% of high blood pressure cases, with an estimated incidence between 0.4 and 0.6 cases per 100,000 people each year, and an average survival of seven years. Pheochromocytoma is a solid tumor with a high genetic component, as heritability can reach 40%. Once diagnosed, its treatment and prognosis are partly conditioned by the associated pathogenic variants that can be documented, especially those related to RET, SDHx, VHL, and NF1 genes. We present the case of a young woman with abdominal pain and high blood pressure, who was found to have a pheochromocytoma. Genetic testing detected a rare and recently discovered pathogenic variant: the SDHA:c.1A&gt;C (p.Met1Leu). The patient responded adequately to the surgical treatment and continued the follow-up without documented recurrences. The diagnostic approach for pheochromocytoma patients must start with a clinical suspicion, followed by metabolite measurement in blood and urine, and finally, imaging. Currently, technology development allows precision medicine applicability. In this case of pheochromocytoma, recent developments in precision medicine resulted in the detection of associated genetic components involving the patient and her family. Adequate screening of the index patient is required for documenting pathogenic variants and better characterizing the disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Morales</LastName><ForeName>Juan</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-0706-0060</Identifier><AffiliationInfo><Affiliation>Departamento de Medicina Interna, Hospital Universitario del Valle, Universidad del Valle, Cali, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arturo</LastName><ForeName>Daniela</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-5914-0601</Identifier><AffiliationInfo><Affiliation>Escuela de Ciencias B&#xe1;sicas, Grupo de Investigaci&#xf3;n en Enfermedades Cong&#xe9;nitas del Metabolismo, Universidad del Valle, Cali, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Folleco</LastName><ForeName>Miguel</ForeName><Initials>M</Initials><Identifier Source="ORCID">0009-0000-3270-2750</Identifier><AffiliationInfo><Affiliation>Secci&#xf3;n de Endocrinolog&#xed;a, Cl&#xed;nica Imbanaco, Cali, Colombia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><Language>spa</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D004740">English Abstract</PublicationType></PublicationTypeList><VernacularTitle>S&#xed;ndrome de feocromocitoma-paraganglioma de tipo 5 como causa de hipertensi&#xf3;n arterial en una paciente colombiana: reporte de caso.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2024</Year><Month>05</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>Colombia</Country><MedlineTA>Biomedica</MedlineTA><NlmUniqueID>8205605</NlmUniqueID><ISSNLinking>0120-4157</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010673" MajorTopicYN="Y">Pheochromocytoma</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000310" MajorTopicYN="Y">Adrenal Gland Neoplasms</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="Y">Hypertension</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003105" MajorTopicYN="N" Type="Geographic">Colombia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010235" MajorTopicYN="N">Paraganglioma</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="spa"><AbstractText>El feocromocitoma es un tumor derivado de las c&#xe9;lulas de la cresta neural con la capacidad de producir sustancias simpaticomim&#xe9;ticas y, por ende, un cuadro cl&#xed;nico particular. Causa menos del 1 % de los casos de hipertensi&#xf3;n arterial sist&#xe9;mica y su incidencia se estima entre 0,4 y 0,6 casos por 100.000 personas cada a&#xf1;o, con una supervivencia media de siete a&#xf1;os. De todos los tumores s&#xf3;lidos, el feocromocitoma tiene un mayor componente gen&#xe9;tico, que puede heredarse hasta en el 40 % de los casos. Una vez diagnosticada la enfermedad, se debe definir el tratamiento y el pron&#xf3;stico, en parte condicionados por las variantes gen&#xe9;ticas asociadas, en especial RET, SDHx, VHL y NF1. Se presenta el caso de una mujer joven con dolor abdominal e hipertensi&#xf3;n arterial sist&#xe9;mica, a quien se le diagnostic&#xf3; feocromocitoma. Al secuenciar el exoma, se identific&#xf3; una variante patog&#xe9;nica extremadamente rara y de reciente descubrimiento: SDHA: c.1A&gt;C (p.Met1Leu). La paciente respondi&#xf3; adecuadamente al tratamiento quir&#xfa;rgico y continu&#xf3; en seguimiento sin recurrencias. El abordaje diagn&#xf3;stico de los pacientes con feocromocitoma comienza con la sospecha cl&#xed;nica, seguida de la medici&#xf3;n de determinados metabolitos en sangre y orina, y, finalmente, los estudios de imagenolog&#xed;a. Los desarrollos tecnol&#xf3;gicos actuales permiten la aplicaci&#xf3;n de la medicina de precisi&#xf3;n en este campo. En este caso de feocromocitoma, se identific&#xf3; un componente gen&#xe9;tico importante que no solo afecta al paciente, sino tambi&#xe9;n, a sus familiares. La tamizaci&#xf3;n adecuada del caso &#xed;ndice permite identificar mutaciones y caracterizar mejor la enfermedad.</AbstractText></OtherAbstract><OtherAbstract Type="Publisher" Language="eng"><AbstractText>Pheochromocytoma is a tumor derived from neural crest cells able to produce sympathomimetic substances and, hence, a particular clinical picture. It is responsible for less than 1% of high blood pressure cases, with an estimated incidence between 0.4 and 0.6 cases per 100,000 people each year, and an average survival of seven years. Pheochromocytoma is a solid tumor with a high genetic component, as heritability can reach 40%. Once diagnosed, its treatment and prognosis are partly conditioned by the associated pathogenic variants that can be documented, especially those related to <i>RET</i>, <i>SDHx</i>, <i>VHL</i>, and <i>NF1</i> genes. We present the case of a young woman with abdominal pain and high blood pressure, who was found to have a pheochromocytoma. Genetic testing detected a rare and recently discovered pathogenic variant: the <i>SDHA</i>:c.1A&gt;C (p.Met1Leu). The patient responded adequately to the surgical treatment and continued the follow-up without documented recurrences. The diagnostic approach for pheochromocytoma patients must start with a clinical suspicion, followed by metabolite measurement in blood and urine, and finally, imaging. Currently, technology development allows precision medicine applicability. In this case of pheochromocytoma, recent developments in precision medicine resulted in the detection of associated genetic components involving the patient and her family. Adequate screening of the index patient is required for documenting pathogenic variants and better characterizing the disease.</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">pheochromocytoma</Keyword><Keyword MajorTopicYN="N">paraganglioma</Keyword><Keyword MajorTopicYN="N">succinate dehydrogenase</Keyword><Keyword MajorTopicYN="N">hypertension</Keyword><Keyword MajorTopicYN="N">neuroendocrine tumors</Keyword><Keyword MajorTopicYN="N">multimodal imaging</Keyword><Keyword MajorTopicYN="N">precision medicine</Keyword></KeywordList><CoiStatement>Conflicto de intereses: Los autores declaran no tener conflictos de intereses.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>7</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>5</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>7</Month><Day>30</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>7</Month><Day>30</Day><Hour>18</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>7</Month><Day>30</Day><Hour>17</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>5</Month><Day>31</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39079135</ArticleId><ArticleId IdType="pmc">PMC11346508</ArticleId><ArticleId IdType="doi">10.7705/biomedica.7152</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Dahia PL. Pheochromocytoma and paraganglioma pathogenesis: Learning from genetic heterogeneity. Nat Rev Cancer. 2014;14:108&#x2013;119. doi: 10.1038/nrc3648.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrc3648</ArticleId><ArticleId IdType="pubmed">24442145</ArticleId></ArticleIdList></Reference><Reference><Citation>Berends AM, Buitenwerf E, de Krijger RR, Veeger NJ, van der Horst-Schrivers AN, Links TP, et al. Incidence of pheochromocytoma and sympathetic paraganglioma in the Netherlands: A nationwide study and systematic review. Eur J Intern Med. 2018;51:68&#x2013;73. doi: 10.1016/j.ejim.2018.01.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejim.2018.01.015</ArticleId><ArticleId IdType="pubmed">29361475</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann HP, Young WF, Jr, Eng C. Pheochromocytoma and paraganglioma. N Engl J Med. 2019;381:552&#x2013;565. doi: 10.1056/NEJMra1806651.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1806651</ArticleId><ArticleId IdType="pubmed">31390501</ArticleId></ArticleIdList></Reference><Reference><Citation>Navarro EP, Osejo MC, Casas LA, Arango LG, Guzm&#xe1;n G. Experiencia en el manejo de feocromocitoma en los &#xfa;ltimos 10 a&#xf1;os: serie de casos. Rev Colomb Endocrinol Diabet Metab. 2016;3:33&#x2013;36. doi: 10.53853/encr.3.3.39.</Citation><ArticleIdList><ArticleId IdType="doi">10.53853/encr.3.3.39</ArticleId></ArticleIdList></Reference><Reference><Citation>Fr&#xe4;nkel F. A case of bilateral, completely latent adrenal tumor and concurrent nephritis with changes in the circulatory system and retinitis. CA Cancer J Clin. 1984;34:93&#x2013;106. doi: 10.3322/canjclin.34.2.93.</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/canjclin.34.2.93</ArticleId><ArticleId IdType="pubmed">6423225</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z, Ma J, Jim&#xe9;nez C, Zhang M. Pheochromocytoma: A clinicopathologic and molecular study of 390 cases from a single center. Am J Surg Pathol. 2021;45:1155&#x2013;1165. doi: 10.1097/PAS.0000000000001768.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PAS.0000000000001768</ArticleId><ArticleId IdType="pubmed">34280940</ArticleId></ArticleIdList></Reference><Reference><Citation>Bausch B, Schiavi F, Ni Y, Welander J, Patocs A, Ngeow J, et al. Clinical characterization of the pheochromocytoma and paraganglioma susceptibility genes SDHA, TMEM127, MAX, and SDHAF2 for gene-informed prevention. JAMA Oncol. 2017;3:1204&#x2013;1212. doi: 10.1001/jamaoncol.2017.0223.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoncol.2017.0223</ArticleId><ArticleId IdType="pmc">PMC5824290</ArticleId><ArticleId IdType="pubmed">28384794</ArticleId></ArticleIdList></Reference><Reference><Citation>N&#xf6;lting S, Ullrich M, Pietzsch J, Ziegler CG, Eisenhofer G, Grossman A, et al. Current management of pheochromocytoma/paraganglioma: A guide for the practicing clinician in the era of precision medicine. Cancers. 2019;11:1505&#x2013;1505. doi: 10.3390/cancers11101505.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers11101505</ArticleId><ArticleId IdType="pmc">PMC6827093</ArticleId><ArticleId IdType="pubmed">31597347</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenders JW, Duh Q-Y, Eisenhofer G, Gimenez-Roqueplo A-P, Grebe SK, Murad MH, et al. Pheochromocytoma and paraganglioma: An endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99:1915&#x2013;1942. doi: 10.1210/jc.2014-1498.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jc.2014-1498</ArticleId><ArticleId IdType="pubmed">24893135</ArticleId></ArticleIdList></Reference><Reference><Citation>Jha A, De Luna K, Balili CA, Millo C, Paraiso CA, Ling A, et al. Clinical, diagnostic, and treatment characteristics of SDHA-related metastatic pheochromocytoma and paraganglioma. Front Oncol. 2019;9:53&#x2013;53. doi: 10.3389/fonc.2019.00053.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2019.00053</ArticleId><ArticleId IdType="pmc">PMC6395427</ArticleId><ArticleId IdType="pubmed">30854332</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnichon N, Bri&#xe8;re J-J, Lib&#xe9; R, Vescovo L, Riviere J, Tissier F, et al. SDHA is a tumor suppressor gene causing paraganglioma. Hum Mol Genet. 2010;19:3011&#x2013;3020. doi: 10.1093/hmg/ddq206.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddq206</ArticleId><ArticleId IdType="pmc">PMC2901140</ArticleId><ArticleId IdType="pubmed">20484225</ArticleId></ArticleIdList></Reference><Reference><Citation>Molina L, Salgado J, Amado S. Feocromocitoma y paraganglioma: un reto m&#xe1;s all&#xe1; de la cl&#xed;nica. Rev Colomb Cancerol. 2021;25:3&#x2013;12. doi: 10.35509/01239015.586.</Citation><ArticleIdList><ArticleId IdType="doi">10.35509/01239015.586</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasconcelos-Prado OD, L&#xf3;pez-Garc&#xed;a AE, Garc&#xed;a-Montalvo IA. Aspectos gen&#xe9;ticos de los feocromocitomas y paragangliomas. J Negat No Posit Results. 2021;6:636&#x2013;650. doi: 10.19230/jonnpr.4020.</Citation><ArticleIdList><ArticleId IdType="doi">10.19230/jonnpr.4020</ArticleId></ArticleIdList></Reference><Reference><Citation>Rueda-Galvis MV, Rom&#xe1;n-Gonzal&#xe9;z A, Agredo-Delgado V. S&#xed;ndrome de feocromocitoma- paraganglioma tipo 5 asociado a mutaci&#xf3;n en el complejo de la succinato deshidrogenasa tipo A (SDHA), a prop&#xf3;sito de un caso. Iatreia. 2023;36 doi: 10.17533/udea.iatreia.187.</Citation><ArticleIdList><ArticleId IdType="doi">10.17533/udea.iatreia.187</ArticleId></ArticleIdList></Reference><Reference><Citation>Welander J, Garvin S, Bohnmark R, Isaksson L, Wiseman RW, S&#xf6;derkvist P, et al. Germline SDHA mutation detected by next-generation sequencing in a young index patient with large paraganglioma. J Clin Endocrinol Metab. 2013;98:e1379-80. doi: 10.1210/jc.2013-1963.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jc.2013-1963</ArticleId><ArticleId IdType="pubmed">23750034</ArticleId></ArticleIdList></Reference><Reference><Citation>van Der Tuin K, Mensenkamp AR, Tops CM, Corssmit EP, Dinjens WN, van de Horst-Schrivers AN, et al. Clinical aspects of SDHA-related pheochromocytoma and paraganglioma: A nationwide study. J Clin Endocrinol Metab. 2018;103:438&#x2013;445. doi: 10.1210/jc.2017-01762.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jc.2017-01762</ArticleId><ArticleId IdType="pubmed">29177515</ArticleId></ArticleIdList></Reference><Reference><Citation>Amar L, Pacak K, Steichen O, Akker SA, Aylwin SJ, Baudin E, et al. International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers. Nat Rev Endocrinol. 2021;17:435&#x2013;444. doi: 10.1038/s41574-021-00492-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41574-021-00492-3</ArticleId><ArticleId IdType="pmc">PMC8205850</ArticleId><ArticleId IdType="pubmed">34021277</ArticleId></ArticleIdList></Reference><Reference><Citation>Ta&#x3ca;eb D, Hicks RJ, Hindi&#xe9; E, Guillet BA, Avram A, Ghedini P, et al. European association of nuclear medicine practice guideline/society of nuclear medicine and molecular imaging procedure standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging. 2019;46:2112&#x2013;2137. doi: 10.1007/s00259-019-04398-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-019-04398-1</ArticleId><ArticleId IdType="pmc">PMC7446938</ArticleId><ArticleId IdType="pubmed">31254038</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38466237</PMID><DateCompleted><Year>2024</Year><Month>06</Month><Day>14</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1941-7225</ISSN><JournalIssue CitedMedium="Internet"><Volume>37</Volume><Issue>7</Issue><PubDate><Year>2024</Year><Month>Jun</Month><Day>14</Day></PubDate></JournalIssue><Title>American journal of hypertension</Title><ISOAbbreviation>Am J Hypertens</ISOAbbreviation></Journal><ArticleTitle>Patients Living With Arterial Hypertension in Mexico: First Insights of The Mexican Registry of Arterial Hypertension (RIHTA Study).</ArticleTitle><Pagination><StartPage>503</StartPage><EndPage>513</EndPage><MedlinePgn>503-513</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/ajh/hpae024</ELocationID><Abstract><AbstractText Label="BACKGROUND">Arterial hypertension is a significant cause of morbidity and mortality in Mexico. However, there is limited evidence to understand blood pressure management and cardiometabolic profiles. Here, we aim to assess the prevalence of controlled and uncontrolled blood pressure, as well as the prevalence of cardiometabolic risk factors among patients from the Mexican Registry of Arterial Hypertension (RIHTA).</AbstractText><AbstractText Label="METHODS">We conducted a cross-sectional analysis of participants living with arterial hypertension registered on RIHTA between December 2021 and April 2023. We used both the 2017 ACC/AHA and 2018 ESC/ESH thresholds to define controlled and uncontrolled arterial hypertension. We considered eleven cardiometabolic risk factors, which include overweight, obesity, central obesity, insulin resistance, diabetes, hypercholesterolemia, hypertriglyceridemia, low HDL-C, high LDL-C, low-eGFR, and high cardiovascular disease (CVD) risk.</AbstractText><AbstractText Label="RESULTS">In a sample of 5,590 participants (female: 61%, n&#x2005;=&#x2005;3,393; median age: 64 [IQR: 56-72] years), the prevalence of uncontrolled hypertension varied significantly, depending on the definition (2017 ACC/AHA: 59.9%, 95% CI: 58.6-61.2 and 2018 ESC/ESH: 20.1%, 95% CI: 19.0-21.2). In the sample, 40.43% exhibited at least 5-6 risk factors, and 32.4% had 3-4 risk factors, chiefly abdominal obesity (83.4%, 95% CI: 82.4-84.4), high LDL-C (59.6%, 95% CI: 58.3-60.9), high CVD risk (57.9%, 95% CI: 56.6-59.2), high triglycerides (56.2%, 95% CI: 54.9-57.5), and low HDL-C (42.2%, 95% CI: 40.9-43.5).</AbstractText><AbstractText Label="CONCLUSIONS">There is a high prevalence of uncontrolled hypertension interlinked with a high burden of cardiometabolic comorbidities in Mexican adults living with arterial hypertension, underscoring the urgent need for targeted interventions and better healthcare policies to reduce the burden of the disease in our country.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2024. Published by Oxford University Press on behalf of American Journal of Hypertension, Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Palomo-Pi&#xf1;&#xf3;n</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-1047-5301</Identifier><AffiliationInfo><Affiliation>Grupo de Expertos en Hipertensi&#xf3;n Arterial M&#xe9;xico (GREHTA), Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Grupo Colaborativo en Hipertensi&#xf3;n Arterial (GCHTA), Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Antonio-Villa</LastName><ForeName>Neftali Eduardo</ForeName><Initials>NE</Initials><Identifier Source="ORCID">0000-0002-6879-1078</Identifier><AffiliationInfo><Affiliation>Departamento de Endocrinolog&#xed;a, Instituto Nacional de Cardiolog&#xed;a Ignacio Ch&#xe1;vez, Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garc&#xed;a-Cort&#xe9;s</LastName><ForeName>Luis Rey</ForeName><Initials>LR</Initials><Identifier Source="ORCID">0000-0003-3325-1458</Identifier><AffiliationInfo><Affiliation>Coordinaci&#xf3;n de Planeaci&#xf3;n y Enlace Institucional, Jefatura de Servicios de Prestaciones M&#xe9;dicas, &#xd3;rgano de Operaci&#xf3;n Administrativa Desconcentrada Regional Estado de M&#xe9;xico Oriente, Instituto Mexicano del Seguro Social, Estado de M&#xe9;xico, Oriente, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moreno-Noguez</LastName><ForeName>Moises</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Grupo de Expertos en Hipertensi&#xf3;n Arterial M&#xe9;xico (GREHTA), Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Coordinaci&#xf3;n Cl&#xed;nica de Educaci&#xf3;n e Investigaci&#xf3;n en Salud, Unidad de Medicina Familiar No. 55 Zumpango, &#xd3;rgano de Operaci&#xf3;n Administrativa Desconcentrada Regional Estado de M&#xe9;xico Oriente, Estado de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alcocer</LastName><ForeName>Luis</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-1657-1695</Identifier><AffiliationInfo><Affiliation>Grupo de Expertos en Hipertensi&#xf3;n Arterial M&#xe9;xico (GREHTA), Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hospital &#xc1;ngeles del Pedregal, Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>&#xc1;lvarez-L&#xf3;pez</LastName><ForeName>Humberto</ForeName><Initials>H</Initials><Identifier Source="ORCID">0009-0009-5282-9834</Identifier><AffiliationInfo><Affiliation>Grupo de Expertos en Hipertensi&#xf3;n Arterial M&#xe9;xico (GREHTA), Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hospital Puerta de Hierro Andares, Zapopan, Jalisco, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cardona-Mu&#xf1;oz</LastName><ForeName>Ernesto G</ForeName><Initials>EG</Initials><Identifier Source="ORCID">0000-0001-7868-667X</Identifier><AffiliationInfo><Affiliation>Grupo de Expertos en Hipertensi&#xf3;n Arterial M&#xe9;xico (GREHTA), Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ch&#xe1;vez-Mendoza</LastName><ForeName>Adolfo</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-1031-3946</Identifier><AffiliationInfo><Affiliation>Grupo de Expertos en Hipertensi&#xf3;n Arterial M&#xe9;xico (GREHTA), Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unidad M&#xe9;dica de Alta Especialidad de Cardiolog&#xed;a, Centro M&#xe9;dico Nacional SXXI, Instituto Mexicano del Seguro Social, Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D&#xed;az-D&#xed;az</LastName><ForeName>Enrique</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Grupo de Expertos en Hipertensi&#xf3;n Arterial M&#xe9;xico (GREHTA), Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unidad M&#xe9;dica de Alta Especialidad de Cardiolog&#xed;a, Centro M&#xe9;dico Nacional SXXI, Instituto Mexicano del Seguro Social, Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Enciso-Mu&#xf1;oz</LastName><ForeName>Jos&#xe9; Manuel</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Grupo de Expertos en Hipertensi&#xf3;n Arterial M&#xe9;xico (GREHTA), Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hospital General Zacatecas "Luz Gonz&#xe1;lez Cosio", Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, Zacatecas, Zacatecas, M&#xe9;xico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Asociaci&#xf3;n Nacional de Cardi&#xf3;logos de M&#xe9;xico, Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galv&#xe1;n-Oseguera</LastName><ForeName>H&#xe9;ctor</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-4933-4883</Identifier><AffiliationInfo><Affiliation>Grupo de Expertos en Hipertensi&#xf3;n Arterial M&#xe9;xico (GREHTA), Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unidad M&#xe9;dica de Alta Especialidad de Cardiolog&#xed;a, Centro M&#xe9;dico Nacional SXXI, Instituto Mexicano del Seguro Social, Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosas-Peralta</LastName><ForeName>Mart&#xed;n</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-8084-8981</Identifier><AffiliationInfo><Affiliation>Grupo de Expertos en Hipertensi&#xf3;n Arterial M&#xe9;xico (GREHTA), Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Titular Academia Nacional de Medicina, Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Mexican Group of Experts on Arterial Hypertension</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Hypertens</MedlineTA><NlmUniqueID>8803676</NlmUniqueID><ISSNLinking>0895-7061</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000959">Antihypertensive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="Y">Hypertension</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008800" MajorTopicYN="N" Type="Geographic">Mexico</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="Y">Registries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000083202" MajorTopicYN="N">Cardiometabolic Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000959" MajorTopicYN="N">Antihypertensive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062186" MajorTopicYN="N">Arterial Pressure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Mexico</Keyword><Keyword MajorTopicYN="N">arterial hypertension</Keyword><Keyword MajorTopicYN="N">blood pressure</Keyword><Keyword MajorTopicYN="N">epidemiology</Keyword><Keyword MajorTopicYN="N">hypertension</Keyword><Keyword MajorTopicYN="N">hypertension management</Keyword></KeywordList><CoiStatement>The authors declare they have no competing interests.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Palomo-Pi&#xf1;&#xf3;n</LastName><ForeName>Silvia</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Antonio-Villa</LastName><ForeName>Neftali Eduardo</ForeName><Initials>NE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garc&#xed;a-Cort&#xe9;s</LastName><ForeName>Luis Rey</ForeName><Initials>LR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alcocer</LastName><ForeName>Luis</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>&#xc1;lvarez L&#xf3;pez</LastName><ForeName>Humberto</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cardona-Mu&#xf1;oz</LastName><ForeName>Ernesto G</ForeName><Initials>EG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ch&#xe1;vez-Mendoza</LastName><ForeName>Adolfo</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>D&#xed;az-D&#xed;az</LastName><ForeName>Enrique</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Galv&#xe1;n-Oseguera</LastName><ForeName>H&#xe9;ctor</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosas-Peralta</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moreno-Noguez</LastName><ForeName>Moises</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>de Los &#xc1;ngeles Dichi Romero</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vargas Guti&#xe9;rrez</LastName><ForeName>Pedro Luis</ForeName><Initials>PL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Figueroa Su&#xe1;rez</LastName><ForeName>Maria Eugenia</ForeName><Initials>ME</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rios Morales</LastName><ForeName>Rub&#xe9;n</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vargas Hern&#xe1;ndez</LastName><ForeName>Francisco</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garc&#xed;a Padilla</LastName><ForeName>Irma Fabiola</ForeName><Initials>IF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zempoalteca Morales</LastName><ForeName>Alfonso</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Herrera Olvera</LastName><ForeName>Imer Guillermo</ForeName><Initials>IG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mendoza L&#xf3;pez</LastName><ForeName>Gloria</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guerrero Morales</LastName><ForeName>Ana Laura</ForeName><Initials>AL</Initials></Investigator><Investigator ValidYN="Y"><LastName>L&#xf3;pez Delgado</LastName><ForeName>Mar&#xed;a Elisa</ForeName><Initials>ME</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gonzales Ram&#xed;rez</LastName><ForeName>Ana Lilia</ForeName><Initials>AL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cruz Toledo</LastName><ForeName>Jairo Enoc</ForeName><Initials>JE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reyes Jim&#xe9;nez</LastName><ForeName>Olivia</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Amaya Mora</LastName><ForeName>Diana</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>P&#xe9;rez Zamora</LastName><ForeName>Isaac</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nava Ayala</LastName><ForeName>Flor Araceli</ForeName><Initials>FA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Anguiano Vel&#xe1;zquez</LastName><ForeName>Tabata Gabriela</ForeName><Initials>TG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jim&#xe9;nez Jalpa</LastName><ForeName>Oscar</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cruz Arce</LastName><ForeName>Ma Adriana</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gonz&#xe1;lez Coronado</LastName><ForeName>Vidal Jos&#xe9;</ForeName><Initials>VJ</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>10</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>1</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>3</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>6</Month><Day>14</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>3</Month><Day>11</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>3</Month><Day>11</Day><Hour>11</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>3</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38466237</ArticleId><ArticleId IdType="pmc">PMC11176274</ArticleId><ArticleId IdType="doi">10.1093/ajh/hpae024</ArticleId><ArticleId IdType="pii">7625454</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zhou B, Perel P, Mensah GA, Ezzati M.. Global epidemiology, health burden and effective interventions for elevated blood pressure and hypertension. Nat Rev Cardiol 2021; 18:785&#x2013;802.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8162166</ArticleId><ArticleId IdType="pubmed">34050340</ArticleId></ArticleIdList></Reference><Reference><Citation>NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet Lond Engl 2021; 398:957&#x2013;980.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8446938</ArticleId><ArticleId IdType="pubmed">34450083</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuchs FD, Whelton PK.. High blood pressure and cardiovascular disease. Hypertension (Dallas, Tex: 1979) 2020; 75:285&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10243231</ArticleId><ArticleId IdType="pubmed">31865786</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruilope LM, Chagas ACP, Brand&#xe3;o AA, G&#xf3;mez-Berroter&#xe1;n R, Alcal&#xe1; JJA, Paris JV, Cerda JJO.. Hypertension in Latin America: current perspectives on trends and characteristics. Hipertens Riesgo Vasc 2017; 34:50&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">28007488</ArticleId></ArticleIdList></Reference><Reference><Citation>Schutte AE, Srinivasapura Venkateshmurthy N, Mohan S, Prabhakaran D.. Hypertension in low- and middle-income countries. Circ Res 2021; 128:808&#x2013;826.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8091106</ArticleId><ArticleId IdType="pubmed">33793340</ArticleId></ArticleIdList></Reference><Reference><Citation>Campos-Nonato I, Hern&#xe1;ndez-Barrera L, Oviedo-Sol&#xed;s C, Ram&#xed;rez-Villalobos D, Hern&#xe1;ndez-Prado B, Barquera S.. Epidemiolog&#xed;a de la hipertensi&#xf3;n arterial en adultos mexicanos: diagn&#xf3;stico, control y tendencias. Ensanut 2020. Salud Publica Mex 2021; 63:692&#x2013;704.</Citation><ArticleIdList><ArticleId IdType="pubmed">35099908</ArticleId></ArticleIdList></Reference><Reference><Citation>Castro-Porras LV, Rojas-Mart&#xed;nez R, Aguilar-Salinas CA, Bello-Chavolla OY, Becerril-Gutierrez C, Escamilla-Nu&#xf1;ez C.. Trends and age-period-cohort effects on hypertension mortality rates from 1998 to 2018 in Mexico. Sci Rep 2021; 11:17553.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8413460</ArticleId><ArticleId IdType="pubmed">34475436</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonio-Villa NE, Bello-Chavolla OY, Ferm&#xed;n-Mart&#xed;nez CA, Aburto JM, Fern&#xe1;ndez-Chirino L, Ram&#xed;rez-Garc&#xed;a D, Pisanty-Alatorre J, Gonz&#xe1;lez-D&#xed;az A, Vargas-V&#xe1;zquez A, Barquera S, Guti&#xe9;rrez-Robledo LM, Seiglie JA.. Socio-demographic inequalities and excess non-COVID-19 mortality during the COVID-19 pandemic: a data-driven analysis of 1,069,174 death certificates in Mexico. Int J Epidemiol 2022; 51:1711&#x2013;1721.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9619535</ArticleId><ArticleId IdType="pubmed">36174226</ArticleId></ArticleIdList></Reference><Reference><Citation>Doubova SV, Garc&#xed;a-Saiso S, P&#xe9;rez-Cuevas R, Sarabia-Gonz&#xe1;lez O, Pacheco-Estrello P, Infante-Casta&#xf1;eda C, Santamar&#xed;a C, Del Pilar Torres-Arreola L, Leslie HH.. Quality governance in a pluralistic health system: Mexican experience and challenges. Lancet Glob Health 2018; 6:e1149&#x2013;e1152.</Citation><ArticleIdList><ArticleId IdType="pubmed">30196095</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcocer L, Rosas M, Estrada A, Ruiz-Gastelum E, Pombo EJ, Cardona EG, Borrayo G, Galvan H, Alvarez H, Gomez-Alvarez E, Chavez A, Beaney T, Clarke J, Poulter NR; MMM-19-Mexico group. May Measurement Month 2019: an analysis of blood pressure screening results from Mexico. Eur Heart J Suppl J Eur Soc Cardiol 2021; 23:B104&#x2013;B106.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8248929</ArticleId><ArticleId IdType="pubmed">34220377</ArticleId></ArticleIdList></Reference><Reference><Citation>Palomo&#x2010;Pi&#xf1;&#xf3;n S, Antonio&#x2010;Villa NE, Garc&#xed;a&#x2010;Cort&#xe9;s LR, &#xc1;lvarez&#x2010;Aguilar C, Gonz&#xe1;lez&#x2010;Palomo E, Bertadillo&#x2010;Mendoza OM, Figueroa&#x2010;Su&#xe1;rez ME, Vargas&#x2010;Hern&#xe1;ndez F, Herrera&#x2010;Olvera IG, Cruz&#x2010;Toledo JE, Cruz&#x2010;Arce MA, Seraf&#xed;n&#x2010;M&#xe9;ndez B, Mu&#xf1;oz&#x2010;Cort&#xe9;s G, Morfin&#x2010;Macias CJ.. Prevalence and characterization of undiagnosed arterial hypertension in the eastern zone of Mexico. J Clin Hypertens 2021; 24:131&#x2013;139.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8845470</ArticleId><ArticleId IdType="pubmed">34962058</ArticleId></ArticleIdList></Reference><Reference><Citation>Meaney A, Ceballos-Reyes G, Guti&#xe9;rrez-Salmean G, Samaniego-M&#xe9;ndez V, Vela-Huerta A, Alcocer L, Z&#xe1;rate-Chavarr&#xed;a E, Mendoza-Castel&#xe1;n E, Olivares-Corichi I, Garc&#xed;a-S&#xe1;nchez R, Mart&#xed;nez-Marroqu&#xed;n Y, Ram&#xed;rez-S&#xe1;nchez I, Meaney E.. Cardiovascular risk factors in a Mexican middle-class urban population. The Lindavista Study. Baseline data. Arch Cardiol Mex 2013; 83:249&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pubmed">24215681</ArticleId></ArticleIdList></Reference><Reference><Citation>Gee ME, Campbell N, Sarrafzadegan N, Jafar T, Khalsa TK, Mangat B, Poulter N, Prabhakaran D, Sonkodi S, Whelton PK, Woodward M, Zhang XH.. Standards for the uniform reporting of hypertension in adults using population survey data: recommendations from the World Hypertension League Expert Committee. J Clin Hypertens (Greenwich) 2014; 16:773&#x2013;781.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8031637</ArticleId><ArticleId IdType="pubmed">25157607</ArticleId></ArticleIdList></Reference><Reference><Citation>Bello-Chavolla OY, Almeda-Valdes P, Gomez-Velasco D, Viveros-Ruiz T, Cruz-Bautista I, Romo-Romo A, S&#xe1;nchez-L&#xe1;zaro D, Meza-Oviedo D, Vargas-V&#xe1;zquez A, Campos OA, Sevilla-Gonz&#xe1;lez MDR, Martag&#xf3;n AJ, Hern&#xe1;ndez LM, Mehta R, Caballeros-Barrag&#xe1;n CR, Aguilar-Salinas CA.. METS-IR, a novel score to evaluate insulin sensitivity, is predictive of visceral adiposity and incident type 2 diabetes. Eur J Endocrinol 2018; 178:533&#x2013;544.</Citation><ArticleIdList><ArticleId IdType="pubmed">29535168</ArticleId></ArticleIdList></Reference><Reference><Citation>Bello-Chavolla OY, Antonio-Villa NE, Vargas-V&#xe1;zquez A, Viveros-Ruiz TL, Almeda-Valdes P, Gomez-Velasco D, Mehta R, Elias-L&#xf3;pez D, Cruz-Bautista I, Rold&#xe1;n-Valadez E, Martag&#xf3;n AJ, Aguilar-Salinas CA.. Metabolic Score for Visceral Fat (METS-VF), a novel estimator of intra-abdominal fat content and cardio-metabolic health. Clin Nutr (Edinburgh, Scotland) 2020; 39:1613&#x2013;1621.</Citation><ArticleIdList><ArticleId IdType="pubmed">31400997</ArticleId></ArticleIdList></Reference><Reference><Citation>Inker LA, Eneanya ND, Coresh J, Tighiouart H, Wang D, Sang Y, Crews DC, Doria A, Estrella MM, Froissart M, Grams ME, Greene T, Grubb A, Gudnason V, Guti&#xe9;rrez OM, Kalil R, Karger AB, Mauer M, Navis G, Nelson RG, Poggio ED, Rodby R, Rossing P, Rule AD, Selvin E, Seegmiller JC, Shlipak MG, Torres VE, Yang W, Ballew SH, Couture SJ, Powe NR, Levey AS; Chronic Kidney Disease Epidemiology Collaboration. New creatinine- and cystatin C-based equations to estimate GFR without race. N Engl J Med 2021; 385:1737&#x2013;1749.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8822996</ArticleId><ArticleId IdType="pubmed">34554658</ArticleId></ArticleIdList></Reference><Reference><Citation>
Pattaro C, Fujii R, Herold J.. 
Nephro: Utilities for Nephrology [Internet]. 2023[Accessed date: 2024 Jan 5]. https://cran.r-project.org/web/packages/nephro/index.html</Citation></Reference><Reference><Citation>Stevens PE, Levin A; Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med 2013; 158:825&#x2013;830.</Citation><ArticleIdList><ArticleId IdType="pubmed">23732715</ArticleId></ArticleIdList></Reference><Reference><Citation>Hajifathalian K, Ueda P, Lu Y, Woodward M, Ahmadvand A, Aguilar-Salinas CA, Azizi F, Cifkova R, Di Cesare M, Eriksen L, Farzadfar F, Ikeda N, Khalili D, Khang YH, Lanska V, Le&#xf3;n-Mu&#xf1;oz L, Magliano D, Msyamboza KP, Oh K, Rodr&#xed;guez-Artalejo F, Rojas-Martinez R, Shaw JE, Stevens GA, Tolstrup J, Zhou B, Salomon JA, Ezzati M, Danaei G.. A novel risk score to predict cardiovascular disease risk in national populations (Globorisk): a pooled analysis of prospective cohorts and health examination surveys. Lancet Diabetes Endocrinol 2015; 3:339&#x2013;355.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7615120</ArticleId><ArticleId IdType="pubmed">25819778</ArticleId></ArticleIdList></Reference><Reference><Citation>
Boyer C.
Globorisk [Internet]. 2022[Accessed date: 2024 Jan 5]. https://github.com/boyercb/globorisk</Citation></Reference><Reference><Citation>Whelton PK, Carey RM, Mancia G, Kreutz R, Bundy JD, Williams B.. Harmonization of the American College of Cardiology/American Heart Association and European Society of Cardiology/European Society of Hypertension Blood Pressure/Hypertension Guidelines: comparisons, reflections, and recommendations. Circulation 2022; 146:868&#x2013;877.</Citation><ArticleIdList><ArticleId IdType="pubmed">35950927</ArticleId></ArticleIdList></Reference><Reference><Citation>
Purnell JQ.
Definitions, classification, and epidemiology of obesity. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferr&#xe8;re B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP (eds), Endotext [Internet]. MDText.com, Inc.: South Dartmouth (MA), 2000[Accessed date: 2023 Aug 1]. http://www.ncbi.nlm.nih.gov/books/NBK279167/</Citation><ArticleIdList><ArticleId IdType="pubmed">25905390</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford ES. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care 2005; 28:2745&#x2013;2749.</Citation><ArticleIdList><ArticleId IdType="pubmed">16249550</ArticleId></ArticleIdList></Reference><Reference><Citation>ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, Collins BS, Hilliard ME, Isaacs D, Johnson EL, Kahan S, Khunti K, Leon J, Lyons SK, Perry ML, Prahalad P, Pratley RE, Seley JJ, Stanton RC, Gabbay RA, on behalf of the American Diabetes Association null; 2. Classification and diagnosis of diabetes: standards of care in diabetes-2023. Diabetes Care 2023; 46:S19&#x2013;S40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9810477</ArticleId><ArticleId IdType="pubmed">36507649</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, Himmelfarb CD, Khera A, Lloyd-Jones D, McEvoy JW, Michos ED, Miedema MD, Mu&#xf1;oz D, Smith SC, Virani SS, Williams KA, Yeboah J, Ziaeian B.. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019; 140:e596&#x2013;e646.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7734661</ArticleId><ArticleId IdType="pubmed">30879355</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipsy RJ. The national cholesterol education program adult treatment panel III guidelines. J Manag Care Pharm 2003; 9:2&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10437161</ArticleId><ArticleId IdType="pubmed">14613351</ArticleId></ArticleIdList></Reference><Reference><Citation>
Vaidya SR, Aeddula NR.. 
Chronic renal failure. In: StatPearls [Internet]. StatPearls Publishing: Treasure Island (FL), 2023[Accessed date: 2023 Aug 1]. Available from:http://www.ncbi.nlm.nih.gov/books/NBK535404/</Citation></Reference><Reference><Citation>
R Core Team. R: A Language and Environment for Statistical Computing [Internet]. R Foundation for Statistical Computing: Vienna, Austria, 2021. [Accessed date: 2024 Jan 5]. Available from: http://www.rstudio.com/</Citation></Reference><Reference><Citation>van Buuren S, Groothuis-Oudshoorn K.. Mice: multivariate imputation by chained equations in R. J Stat Softw 2011; 45:1&#x2013;67.</Citation></Reference><Reference><Citation>
Nunes MS and ES with contributions from T, Heuer C, Marshall J, Sanchez J, Thornton R, Reiczigel J, Robison-Cox J, Sebastiani P, Solymos P, Yoshida K, Jones G, Pirikahu S, Firestone S, Kyle R, Popp J, Jay M, Reynard C, Cheung A, Singanallur N, Rabiee AS and A. epiR: Tools for the Analysis of Epidemiological Data [Internet]. 2022[Accessed date: 2022 Apr 5]. https://CRAN.R-project.org/package=epiR</Citation></Reference><Reference><Citation>Orawo LA. Confidence intervals for the binomial proportion: a comparison of four methods. Open J Stat 2021; 11:806&#x2013;816.</Citation></Reference><Reference><Citation>Reed JF. Better binomial confidence intervals. J Mod Appl Stat Methods 2007; 6:153&#x2013;161.</Citation></Reference><Reference><Citation>
Wickham H, Chang W, Henry L, Pedersen TL, Takahashi K, Wilke C, Woo K, Yutani H, Dunnington D, RStudio. ggplot2: Create Elegant Data Visualisations Using the Grammar of Graphics [Internet]. 2022[Accessed date: cited 2022 Aug 6]. https://CRAN.R-project.org/package=ggplot2</Citation></Reference><Reference><Citation>Leslie HH, Doubova SV, P&#xe9;rez-Cuevas R.. Assessing health system performance: effective coverage at the Mexican Institute of Social Security. Health Policy Plan 2019; 34:ii67&#x2013;ii76.</Citation><ArticleIdList><ArticleId IdType="pubmed">31723962</ArticleId></ArticleIdList></Reference><Reference><Citation>Bautista-Arredondo S, Vargas-Flores A, Moreno-Aguilar LA, Colchero MA.. Utilizaci&#xf3;n de servicios de salud en M&#xe9;xico: cascada de atenci&#xf3;n primaria en 2022. Salud Publica Mex 2023; 65:s15&#x2013;s22.</Citation><ArticleIdList><ArticleId IdType="pubmed">38060950</ArticleId></ArticleIdList></Reference><Reference><Citation>Vel&#xe1;zquez Monroy O, Rosas Peralta M, Lara Esqueda A, Pastel&#xed;n Hern&#xe1;ndez G, Attie F, Tapia Conyer R.. Hipertensi&#xf3;n arterial en M&#xe9;xico: Resultados de la Encuesta Nacional de Salud (ENSA) 2000. Arch Cardiol M&#xe9;xico 2002; 72:71&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">11933703</ArticleId></ArticleIdList></Reference><Reference><Citation>Campos-Nonato I, Hern&#xe1;ndez-Barrera L, Rojas-Mart&#xed;nez R.. Hipertensi&#xf3;n arterial: prevalencia, diagn&#xf3;stico oportuno, control y tendencias en adultos mexicanos. Salud P&#xfa;blica M&#xe9;xico 2013; 55:144&#x2013;150.</Citation><ArticleIdList><ArticleId IdType="pubmed">24626690</ArticleId></ArticleIdList></Reference><Reference><Citation>Campos-Nonato I, Hern&#xe1;ndez-Barrera L, Pedroza-Tob&#xed;as A, Medina C, Barquera S.. [Hypertension in Mexican adults: prevalence, diagnosis and type of treatment. Ensanut MC 2016.]. Salud Publica Mex 2018; 60:233&#x2013;243.</Citation><ArticleIdList><ArticleId IdType="pubmed">29746740</ArticleId></ArticleIdList></Reference><Reference><Citation>Campos-Nonato I, Oviedo-Sol&#xed;s C, Vargas-Meza J, Ram&#xed;rez-Villalobos D, Medina-Garc&#xed;a C, G&#xf3;mez-&#xc1;lvarez E, Hern&#xe1;ndez-Barrera L, Barquera S.. Prevalencia, tratamiento y control de la hipertensi&#xf3;n arterial en adultos mexicanos: resultados de la Ensanut 2022. Salud P&#xfa;blica de M&#xe9;xico 2023; 65:s169&#x2013;s180.</Citation><ArticleIdList><ArticleId IdType="pubmed">38060966</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcocer L, Chavez A, Gomez-Alvarez E, Espinosa C, Pombo J, Beaney T, Ster AC, Poulter NR; MMM18-Mexico investigators. May Measurement Month 2018: an analysis of blood pressure screening results from Mexico. Eur Heart J Suppl J Eur Soc Cardiol 2020; 22:H89&#x2013;H91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7455279</ArticleId><ArticleId IdType="pubmed">32884481</ArticleId></ArticleIdList></Reference><Reference><Citation>Beaney T, Wang W, Schlaich MP, Schutte AE, Stergiou GS, Alcocer L, Alsaid J, Diaz AB, Hernandez-Hernandez R, Ishaq M, Jozwiak J, Khan N, Kiru G, McCardle H, Odili AN, Pyun WB, Romero CA, Wang J, Poulter NR; MMM Investigators. Global blood pressure screening during the COVID-19 pandemic: results from the May Measurement Month 2021 campaign. J Hypertens 2023; 41:1446&#x2013;1455.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10399936</ArticleId><ArticleId IdType="pubmed">37337866</ArticleId></ArticleIdList></Reference><Reference><Citation>Muntner P, Hardy ST, Fine LJ, Jaeger BC, Wozniak G, Levitan EB, Colantonio LD.. Trends in blood pressure control among US adults with hypertension, 1999&#x2013;2000 to 2017&#x2013;2018. JAMA 2020; 324:1190&#x2013;1200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7489367</ArticleId><ArticleId IdType="pubmed">32902588</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaffe MG, Young JD.. The Kaiser Permanente Northern California story: improving hypertension control from 44% to 90% in 13 years (2000 to 2013). J Clin Hypertens (Greenwich) 2016; 18:260&#x2013;261.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8032167</ArticleId><ArticleId IdType="pubmed">26939059</ArticleId></ArticleIdList></Reference><Reference><Citation>Campos-Nonato I, Galv&#xe1;n-Valencia O, Hern&#xe1;ndez-Barrera L, Oviedo-Sol&#xed;s C, Barquera S.. Prevalencia de obesidad y factores de riesgo asociados en adultos mexicanos: resultados de la Ensanut 2022. Salud Publica Mex 2023; 65:s238&#x2013;s247.</Citation><ArticleIdList><ArticleId IdType="pubmed">38060949</ArticleId></ArticleIdList></Reference><Reference><Citation>Barquera S, Rivera JA.. Obesity in Mexico: rapid epidemiological transition and food industry interference in health policies. Lancet Diabetes Endocrinol 2020; 8:746&#x2013;747.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7434327</ArticleId><ArticleId IdType="pubmed">32822599</ArticleId></ArticleIdList></Reference><Reference><Citation>Morales-Villegas EC, Yarleque C, Almeida ML.. Management of hypertension and dyslipidemia in Mexico: evidence, gaps, and approach. Arch Cardiol M&#xe9;xico 2023; 93:77&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10161831</ArticleId><ArticleId IdType="pubmed">35359036</ArticleId></ArticleIdList></Reference><Reference><Citation>Hern&#xe1;ndez-Alcaraz C, Aguilar-Salinas CA, Mendoza-Herrera K, Pedroza-Tob&#xed;as A, Villalpando S, Shamah-Levy T, Rivera-Dommarco J, Hern&#xe1;ndez-&#xc1;vila M, Barquera S, Hern&#xe1;ndez-Alcaraz C, Aguilar-Salinas CA, Mendoza-Herrera K, Pedroza-Tob&#xed;as A, Villalpando S, Shamah-Levy T, Rivera-Dommarco J, Hern&#xe1;ndez-&#xc1;vila M, Barquera S.. Dyslipidemia prevalence, awareness, treatment and control in Mexico: results of the Ensanut 2012. Salud P&#xfa;blica M&#xe9;xico 2020; 62:137&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pubmed">32237556</ArticleId></ArticleIdList></Reference><Reference><Citation>Basto-Abreu A, L&#xf3;pez-Olmedo N, Rojas-Mart&#xed;nez R, Aguilar-Salinas CA, Moreno-Banda GL, Carnalla M, Rivera JA, Romero-Martinez M, Barquera S, Barrientos-Guti&#xe9;rrez T.. Prevalencia de prediabetes y diabetes en M&#xe9;xico: Ensanut 2022. Salud P&#xfa;blica de M&#xe9;xico 2023; 65:s163&#x2013;s168.</Citation><ArticleIdList><ArticleId IdType="pubmed">38060942</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou MS, Wang A, Yu H.. Link between insulin resistance and hypertension: What is the evidence from evolutionary biology? Diabetol Metab Syndr 2014; 6:12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3996172</ArticleId><ArticleId IdType="pubmed">24485020</ArticleId></ArticleIdList></Reference><Reference><Citation>Agudelo-Botero M, Valdez-Ortiz R, Giraldo-Rodr&#xed;guez L, Gonz&#xe1;lez-Robledo MC, Mino-Le&#xf3;n D, Rosales-Herrera MF, Cahuana-Hurtado L, Rojas-Russell ME, D&#xe1;vila-Cervantes CA.. Overview of the burden of chronic kidney disease in Mexico: secondary data analysis based on the Global Burden of Disease Study 2017. BMJ Open 2020; 10:e035285.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7170614</ArticleId><ArticleId IdType="pubmed">32213523</ArticleId></ArticleIdList></Reference><Reference><Citation>Medina C, J&#xe1;uregui A, Hern&#xe1;ndez C, Gonz&#xe1;lez C, Olvera AG, Blas N, Campos I, Barquera S.. Prevalencia de comportamientos del movimiento en poblaci&#xf3;n mexicana. Salud P&#xfa;blica M&#xe9;xico 2023; 65:s259&#x2013;s267.</Citation><ArticleIdList><ArticleId IdType="pubmed">38060964</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38060949</PMID><DateCompleted><Year>2023</Year><Month>12</Month><Day>16</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>16</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1606-7916</ISSN><JournalIssue CitedMedium="Internet"><Volume>65</Volume><PubDate><Year>2023</Year><Month>Jun</Month><Day>14</Day></PubDate></JournalIssue><Title>Salud publica de Mexico</Title><ISOAbbreviation>Salud Publica Mex</ISOAbbreviation></Journal><ArticleTitle>[Not Available].</ArticleTitle><Pagination><StartPage>s238</StartPage><EndPage>s247</EndPage><MedlinePgn>s238-s247</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.21149/14809</ELocationID><Abstract><AbstractText Label="OBJETIVO" NlmCategory="OBJECTIVE">Describir la prevalencia de obesidad en adultos, medida a trav&#xe9;s del &#xed;ndice de masa corporal (IMC) y la circunferencia de cintura (CC), estratificando por factores de riesgo y comorbilidades. Material y m&#xe9;todos. Se analiz&#xf3; la informaci&#xf3;n de 8 563 participantes en la Encuesta Nacional de Salud y Nutrici&#xf3;n 2022 (Ensanut 2022). Se clasific&#xf3; la obesidad por IMC y por CC. Se calcularon razones de momios (RM) para asociar la obesidad con factores de riesgo y diagn&#xf3;stico de comorbilidades.</AbstractText><AbstractText Label="RESULTADOS" NlmCategory="RESULTS">La prevalencia de sobrepeso fue 38.3%, obesidad 36.9% y obesidad abdominal (OA) 81.0%. Las mujeres tuvieron una mayor RM (1.4) de tener obesidad y OA (2.5). Los adultos con obesidad ten&#xed;an una mayor posibilidad de tener diagn&#xf3;stico de diabetes (RM 1.7), hipertensi&#xf3;n (3.6) y dislipidemia (RM 2.3) que los adultos con IMC normal.</AbstractText><AbstractText Label="CONCLUSIONES" NlmCategory="CONCLUSIONS">La prevalencia de obesidad en adultos mexicanos es una de las m&#xe1;s altas a nivel mundial y est&#xe1; asociada con los factores de riesgo y enfermedades cr&#xf3;nicas m&#xe1;s frecuentes. Se requieren pol&#xed;ticas p&#xfa;blicas multisectoriales para prevenir y controlar la obesidad.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Campos-Nonato</LastName><ForeName>Ismael</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n en Nutrici&#xf3;n y Salud, Instituto Nacional de Salud P&#xfa;blica. Cuernavaca, Morelos, M&#xe9;xico.. icampos@insp.mx.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galv&#xe1;n-Valencia</LastName><ForeName>&#xd3;scar</ForeName><Initials>&#xd3;</Initials><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n en Nutrici&#xf3;n y Salud, Instituto Nacional de Salud P&#xfa;blica. Cuernavaca, Morelos, M&#xe9;xico.. oscgalval@hotmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hern&#xe1;ndez-Barrera</LastName><ForeName>Luc&#xed;a</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n en Nutrici&#xf3;n y Salud, Instituto Nacional de Salud P&#xfa;blica. Cuernavaca, Morelos, M&#xe9;xico.. lhernan@insp.mx.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oviedo-Sol&#xed;s</LastName><ForeName>Cecilia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n en Nutrici&#xf3;n y Salud, Instituto Nacional de Salud P&#xfa;blica. Cuernavaca, Morelos, M&#xe9;xico.. investigador72@insp.mx.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barquera</LastName><ForeName>Sim&#xf3;n</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n en Nutrici&#xf3;n y Salud, Instituto Nacional de Salud P&#xfa;blica. Cuernavaca, Morelos, M&#xe9;xico.. sbarquera@insp.mx.</Affiliation></AffiliationInfo></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Prevalencia de obesidad y factores de riesgo asociados en adultos mexicanos: resultados de la Ensanut 2022.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Mexico</Country><MedlineTA>Salud Publica Mex</MedlineTA><NlmUniqueID>0404371</NlmUniqueID><ISSNLinking>0036-3634</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>3</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>12</Month><Day>7</Day><Hour>18</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>12</Month><Day>7</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>12</Month><Day>7</Day><Hour>16</Hour><Minute>17</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38060949</ArticleId><ArticleId IdType="doi">10.21149/14809</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37980226</PMID><DateCompleted><Year>2023</Year><Month>12</Month><Day>05</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1989-4805</ISSN><JournalIssue CitedMedium="Internet"><Volume>40</Volume><Issue>4</Issue><PubDate><Year>2023</Year><Season>Oct-Dec</Season></PubDate></JournalIssue><Title>Hipertension y riesgo vascular</Title><ISOAbbreviation>Hipertens Riesgo Vasc</ISOAbbreviation></Journal><ArticleTitle>[Lower urinary tract symptoms in patients with arterial hypertension. Cardiovascular risk and impact on their quality of life].</ArticleTitle><Pagination><StartPage>205</StartPage><EndPage>214</EndPage><MedlinePgn>205-214</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.hipert.2023.05.008</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1889-1837(23)00035-1</ELocationID><Abstract><AbstractText Label="OBJETIVES" NlmCategory="OBJECTIVE">To determine the prevalence of erectile lower urinary tract symptoms in hypertensive patients, cardiovascular risk and the impact on quality of life.</AbstractText><AbstractText Label="MATERIAL AND METHODS" NlmCategory="METHODS">Setting: Health Center (Vilagarcia, Pontevedra).</AbstractText><AbstractText Label="PERIOD" NlmCategory="METHODS">April 2015-June 2017.</AbstractText><AbstractText Label="INCLUSION CRITERIA" NlmCategory="METHODS">Hypertensive patient with informed consent.</AbstractText><AbstractText Label="MEASUREMENTS" NlmCategory="METHODS">sociodemographic variables, toxic habits, comorbidity, blood pressure, cardiovascular risk, analytical and examination parameters. Questionaries: International Prostate Symptom Scale (IPSS), International Index of Erectile Function (IIEF-15) and quality of life in arterial hypertension (MINICHAL).</AbstractText><AbstractText Label="SAMPLE SIZE" NlmCategory="METHODS">n=262 (&#xb1; 6% accuracy, 95% confidence).</AbstractText><AbstractText Label="STATISTICAL ANALYSIS" NlmCategory="METHODS">Bivariate and multivariate statistical analysis. Informed consent and ethics committee approval were obtained (2024/237) RESULTS: The mean age was 65.84 (12.70), and mean hypertension duration of 13.25 (9.84) years. 76.7% reported lower tract urinary symptoms, 91.6% being mild. The bivariate analysis showed an association with the variables: age, educational level, profession, work activity, tobacco, benign prostatic hypertrophy, years of diagnosis, concomitant medication, Framingham-Wilson score, electrocardiogram, glycated hemoglobin, glomerular filtration (Crockroft-Gault), LDL-cholesterol, somatic manifestations (MINICHAL), erectile dysfunction. The multivariate analysis showed increased risk with:abdominal obesity, pathological electrocardiogram, high risk of Framingham-Wilson score, erectile dysfunction, use of hypouricemics agents and decreased with not smoking and use diuretics.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Three quarters of hypertensive men presented lower urinary tract symptoms, increasing the risk of cardiovascular disease early according to the Framingham-Wilson score. Other predictive factors were: abdominal obesity, tobacco, pathological electrocardiogram, high Framingham-Wilson score, erectile dysfunction, use of hypouricemics agents.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023. Publicado por Elsevier Espa&#xf1;a, S.L.U.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Diosdado-Figueiredo</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Equipo de Atenci&#xf3;n Primaria, Vilanova de Arousa, Pontevedra, Espa&#xf1;a. Electronic address: Monica.Diosdado.Figueiredo@sergas.es.</Affiliation></AffiliationInfo></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>S&#xed;ntomas del tracto urinario inferior en pacientes con hipertensi&#xf3;n arterial. Riesgo cardiovascular e impacto en su calidad de vida.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2023</Year><Month>11</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Hipertens Riesgo Vasc</MedlineTA><NlmUniqueID>101510649</NlmUniqueID><ISSNLinking>1889-1837</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007172" MajorTopicYN="Y">Erectile Dysfunction</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="Y">Cardiovascular Diseases</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056128" MajorTopicYN="N">Obesity, Abdominal</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059411" MajorTopicYN="Y">Lower Urinary Tract Symptoms</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="Y">Hypertension</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000082742" MajorTopicYN="N">Heart Disease Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Abdominal obesity</Keyword><Keyword MajorTopicYN="N">Cardiovascular risk</Keyword><Keyword MajorTopicYN="N">Disfunci&#xf3;n er&#xe9;ctil</Keyword><Keyword MajorTopicYN="N">Erectile dysfunction</Keyword><Keyword MajorTopicYN="N">Hipouricemiantes</Keyword><Keyword MajorTopicYN="N">Hypouricemic agents</Keyword><Keyword MajorTopicYN="N">Lower urinary tract symptoms</Keyword><Keyword MajorTopicYN="N">Obesidad abdominal</Keyword><Keyword MajorTopicYN="N">Riesgo cardiovascular</Keyword><Keyword MajorTopicYN="N">S&#xed;ntomas del tracto urinario inferior</Keyword><Keyword MajorTopicYN="N">Tabaco</Keyword><Keyword MajorTopicYN="N">Tobacco</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>5</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>12</Month><Day>5</Day><Hour>12</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>11</Month><Day>19</Day><Hour>9</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>11</Month><Day>18</Day><Hour>22</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37980226</ArticleId><ArticleId IdType="doi">10.1016/j.hipert.2023.05.008</ArticleId><ArticleId IdType="pii">S1889-1837(23)00035-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40099105</PMID><DateCompleted><Year>2025</Year><Month>03</Month><Day>18</Day></DateCompleted><DateRevised><Year>2025</Year><Month>03</Month><Day>19</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2539-3596</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>6</Issue><PubDate><Year>2023</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Revista de salud publica (Bogota, Colombia)</Title><ISOAbbreviation>Rev Salud Publica (Bogota)</ISOAbbreviation></Journal><ArticleTitle>[Hypertension-abdominal obesity phenotype as an indicator of dysglycaemia and insulin resistance].</ArticleTitle><Pagination><StartPage>110831</StartPage><MedlinePgn>110831</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">110831</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.15446/rsap.V25n6.110831</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">To determine the usefulness of the hypertension-abdominal obesity phenotype as an indicator of dysglycaemia and insulin resistance.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="UNASSIGNED">Cross-sectional descriptive study of 964 adults (449 women and 515 men) who attended the Institute of Endocrinology with risk of <i>diabetes melli</i>tus. Demographic (age, sex, skin colour), clinical (blood pressure and acanthosis nigricans), anthropometric (weight, height, waist circumference and body mass index) and laboratory (basal and oral glucose tolerance test-stimulated blood glucose and insulinaemia) variables were analysed. The insulin resistance index was calculated. The abdominal hypertension-obesity phenotype was defined as the presence of systolic pressure &#x2265;130 mm Hg and/or diastolic pressure &#x2265;80 mm Hg or treated hypertension, waist circumference &#x2265;80 cm in women and &#x2265;90 cm in men. Sensitivity, specificity and predictive values of the abdominal obesity hypertension phenotype were calculated to identify dysglycaemia and insulin resistance.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Individuals with the hypertension-abdominal obesity phenotype showed a higher proportion of impaired glucose metabolism and insulin resistance than those without the phenotype (p&lt;0.0001). The hypertension-abdominal obesity phenotype better identifies persons with the presence of double prediabetes, <i>diabetes mellitus</i> and insulin resistance, as they show high sensitivities (85.9%, 77.5%, and 68.9%, respectively), and high negatives predictive values (97.9%, 95.8%, and 74.0%, respectively).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">The hypertension-abdominal obesity phenotype is a simple, useful option for identifying persons with dysglycaemia, and insulin resistance.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cabrera-Rode</LastName><ForeName>Eduardo</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>EC: Biol. Ph. D. Ciencias Biol&#xf3;gicas, Universidad de la Habana. Instituto de Endocrinolog&#xed;a (INEN), Universidad de Ciencias M&#xe9;dicas de la Habana. La Habana, Cuba. eduardo.cabrerarode@gmail.com Instituto de Endocrinolog&#xed;a (INEN) Universidad de Ciencias M&#xe9;dicas de la Habana La Habana Cuba.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loaiza-Romero</LastName><ForeName>Brayam Javier</ForeName><Initials>BJ</Initials><AffiliationInfo><Affiliation>BL: MD. Esp. Endocrinolog&#xed;a. Instituto de Endocrinolog&#xed;a (INEN), Universidad de Ciencias M&#xe9;dicas de la Habana. La Habana, Cuba. brayamloaiza@gmail.com Universidad de Ciencias M&#xe9;dicas de la Habana La Habana Cuba.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodr&#xed;guez-Acosta</LastName><ForeName>Janet</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>JR: Tecnol. Salud. Esp. Laboratorio Cl&#xed;nico. Instituto de Endocrinolog&#xed;a (INEN), Universidad de Ciencias M&#xe9;dicas de la Habana. La Habana, Cuba. yanetra@infomed.sld.cu Universidad de Ciencias M&#xe9;dicas de la Habana La Habana Cuba yanetra@infomed.sld.cu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cubas-Due&#xf1;as</LastName><ForeName>Ileana</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>IC: MD. Esp. Inmunolog&#xed;a. Instituto de Endocrinolog&#xed;a (INEN), Universidad de Ciencias M&#xe9;dicas de la Habana. La Habana, Cuba. ileana.cubas77@gmail.com Universidad de Ciencias M&#xe9;dicas de la Habana La Habana Cuba.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hern&#xe1;ndez-Rodr&#xed;guez</LastName><ForeName>Jos&#xe9;</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>JH: MD. Esp. Endocrinolog&#xed;a. Instituto de Endocrinolog&#xed;a (INEN), Universidad de Ciencias M&#xe9;dicas de la Habana. La Habana, Cuba. pepehdez@infomed.sld.cu Universidad de Ciencias M&#xe9;dicas de la Habana La Habana Cuba.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D&#xed;az-D&#xed;az</LastName><ForeName>Oscar</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>OD: MD. Esp. Endocrinolog&#xed;a. Instituto de Endocrinolog&#xed;a (INEN), Universidad de Ciencias M&#xe9;dicas de la Habana. La Habana, Cuba. diazdiaz@infomed.sld.cu Universidad de Ciencias M&#xe9;dicas de la Habana La Habana Cuba.</Affiliation></AffiliationInfo></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Fenotipo hipertensi&#xf3;n-obesidad abdominal como indicador de disglucemia y resistencia a la insulina.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2023</Year><Month>11</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Colombia</Country><MedlineTA>Rev Salud Publica (Bogota)</MedlineTA><NlmUniqueID>100936348</NlmUniqueID><ISSNLinking>0124-0064</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007333" MajorTopicYN="Y">Insulin Resistance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="Y">Hypertension</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056128" MajorTopicYN="Y">Obesity, Abdominal</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="Y">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="spa"><AbstractText Label="OBJETIVO">Determinar la utilidad del fenotipo hipertensi&#xf3;n-obesidad abdominal como indicador de disglucemia y resistencia a la insulina.</AbstractText><AbstractText Label="MATERIAL Y M&#xc9;TODOS">Estudio descriptivo transversal con 964 personas adultas (449 mujeres y 515 hombres), que asistieron al Instituto de Endocrinolog&#xed;a con riesgo de <i>diabetes mellitus.</i> Se analizaron variables demogr&#xe1;ficas (edad, sexo, color de la piel), cl&#xed;nicas (tensi&#xf3;n arterial y Acantosis nigricans), antropom&#xe9;tricas (peso, talla, circunferencia de la cintura e &#xed;ndice de masa corporal) y de laboratorio (glucemia basal y estimulada con la prueba de tolerancia a la glucosa oral e insulinemia). Se calcul&#xf3; el &#xed;ndice de resistencia a la insulina. El fenotipo hipertensi&#xf3;n-obesidad abdominal se defini&#xf3; como la presencia de presi&#xf3;n sist&#xf3;lica &#x2265;130 mm Hg o presi&#xf3;n diast&#xf3;lica &#x2265;80 mm Hg o hipertensi&#xf3;n arterial tratada, circunferencia de cintura &#x2265;80 cm en mujeres y &#x2265;90 cm en hombres. Se calcul&#xf3; la sensibilidad, la especificidad y los valores predictivos del fenotipo hipertensi&#xf3;n obesidad abdominal para identificar disglucemia y resistencia a la insulina.</AbstractText><AbstractText Label="RESULTADOS">Los individuos con el fenotipo hipertensi&#xf3;n-obesidad abdominal mostraron mayor proporci&#xf3;n de alteraciones del metabolismo de la glucosa y de resistencia a la insulina que las personas sin el fenotipo (p&lt;0,0001). El fenotipo hipertensi&#xf3;n-obesidad abdominal identifica mejor a personas con presencia de prediabetes doble, <i>diabetes mellitus</i> y resistencia a la insulina, pues muestran sensibilidades altas (85,9%, 77,5%, y 68,9%, respectivamente) y valores predictivos negativos altos (97,9%, 95,8%, y 74,0%, respectivamente).</AbstractText><AbstractText Label="CONCLUSIONES">El fenotipo hipertensi&#xf3;n-obesidad abdominal es una opci&#xf3;n sencilla, &#xfa;til para identificar a personas con disglucemia y resistencia a la insulina.</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Abdominal obesity</Keyword><Keyword MajorTopicYN="N">diabetes mellitus</Keyword><Keyword MajorTopicYN="N">dysglycaemia</Keyword><Keyword MajorTopicYN="N">hypertension</Keyword><Keyword MajorTopicYN="N">insulin resistance (source: MeSH, NLM)</Keyword><Keyword MajorTopicYN="N">prediabetes</Keyword></KeywordList><CoiStatement>Conflictos de intereses: Ninguno.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>6</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>10</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>10</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>11</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>11</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>3</Month><Day>18</Day><Hour>4</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>11</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40099105</ArticleId><ArticleId IdType="pmc">PMC11665031</ArticleId><ArticleId IdType="doi">10.15446/rsap.V25n6.110831</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>M&#xfc;ller TD, Bl&#xfc;her M, Tschbp MH, DiMarchi RD. Anti-obesity drug disco-very: advances and challenges. Nat Rev Drug Discov. 2022;21(3):201&#x2013;223. doi: 10.1038/s41573-021-00337-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41573-021-00337-8</ArticleId><ArticleId IdType="pmc">PMC8609996</ArticleId><ArticleId IdType="pubmed">34815532</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang P, Sun X, Jin H, Zhang F-L, Guo Z-N, Yang Y. Association be-tween obesity type and common vascular and metabolic diseases: A cross-sectional study. Front Endocrinol (Lausanne) 2019;10:900&#x2013;900. doi: 10.3389/fendo.2019.00900.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2019.00900</ArticleId><ArticleId IdType="pmc">PMC6962099</ArticleId><ArticleId IdType="pubmed">31998234</ArticleId></ArticleIdList></Reference><Reference><Citation>Oussaada SM, van Galen KA, Cooiman MI, Kleinendorst L, Hazebroek EJ, van Haelst MM, et al. The pathogenesis of obesity. Metabolism. 2019;92:26&#x2013;36. doi: 10.1016/j.metabol.2018.12.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.metabol.2018.12.012</ArticleId><ArticleId IdType="pubmed">30639246</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi D, Choi S, Son JS, Oh SW, Park SM. Impact of discrepancies in general and abdominal obesity on major adverse cardiac events. J Am Heart Assoc. 2019;8(18):e013471.  https://do.org/10.1161/JAHA.119.013471</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.119.013471</ArticleId><ArticleId IdType="pmc">PMC6818009</ArticleId><ArticleId IdType="pubmed">31480883</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Howard AG, Adair LS, Wang H, Avery CL, Gordon-Larsen P. Waist circumference change is associated with blood pressure change independent of BMI change. Obesity (Silver Spring) 2020;28(1):146&#x2013;153. doi: 10.1002/oby.22638.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/oby.22638</ArticleId><ArticleId IdType="pmc">PMC6925347</ArticleId><ArticleId IdType="pubmed">31755247</ArticleId></ArticleIdList></Reference><Reference><Citation>Coutinho T, Goel K, Correa de S&#xe1; D, Carter RE, Hodge DO, Kragelund C, et al. Combining body mass index with measures of central obesity in the assessment of mortality in subjects with coronary disease: role of "normal weight central obesity". J Am Coll Cardiol. 2013;61(5):553&#x2013;560. doi: 10.1016/j.jacc.2012.10.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2012.10.035</ArticleId><ArticleId IdType="pubmed">23369419</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HY, Kim JK, Shin GG, Han JA, Kim JW. Association between abdominal obesity and cardiovascular risk factors in adults with normal body mass index: Based on the sixth Korea national health and nutrition examination survey. J Obes Metab Syndr. 2019;28(4):262&#x2013;270. doi: 10.7570/jomes.2019.28.4.262.</Citation><ArticleIdList><ArticleId IdType="doi">10.7570/jomes.2019.28.4.262</ArticleId><ArticleId IdType="pmc">PMC6939698</ArticleId><ArticleId IdType="pubmed">31909369</ArticleId></ArticleIdList></Reference><Reference><Citation>Sangr&#xf3;s FJ, Torrecilla J, Gir&#xe1;ldez-Garc&#xed;a C, Carrillo L, Mancera J, Mur T, et al. Association of general and abdominal obesity with hypertension, dyslipidemia and prediabetes in the PREDAPS Study. Rev Esp Cardiol (Engl Ed) 2018;71(3):170&#x2013;177. doi: 10.1016/j.rec.2017.04.035. English, Spanish.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rec.2017.04.035</ArticleId><ArticleId IdType="pubmed">28789915</ArticleId></ArticleIdList></Reference><Reference><Citation>Di&#xe9;guez-Mart&#xed;nez M, Miguel-Soca PE, Rodr&#xed;guez-Hern&#xe1;ndez R, L&#xf3;pez-B&#xe1;ster J, Ponce-de Le&#xf3;n D. Prevalencia de obesidad abdominal y factores de riesgo cardiovascular asociados en adultos j&#xf3;venes.  [2022 Mayo 14];Rev Cubana Salud P&#xfa;blica. 2017 43(3):1&#x2013;16. Internet. Disponible en:  https://bit.ly/49SGSev
.</Citation></Reference><Reference><Citation>Ribeiro FB, de C&#xe1;ssia da Silva C, Vasques ACJ, Zambon MP, De Bernardi Rodrigues AM, Camilo DF, et al. Hypertriglyceridemic waist phenotype indicates insulin resistance in adolescents: validation study front hyperglycemic clamp-Brazilian Metabolic Syndrome Study (BRAMS) Diabetol Metab Syndr. 2015;7(1):A145&#x2013;A145. doi: 10.1186/1758-5996-7-s1-a145.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1758-5996-7-s1-a145</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#xed;az-Santana MV, Su&#xe1;rez-P&#xe9;rez EL, Ortiz-Mart&#xed;nez AP, Guzm&#xe1;n-Serrano M, P&#xe9;rez-Cardona CM. Association between the hypertriglyceridemic waist phenotype, prediabetes, and diabetes mellitus among adults in Puerto Rico. J Immigr Minor Health. 2016;18(1):102&#x2013;109. doi: 10.1007/s10903-014-9985-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10903-014-9985-y</ArticleId><ArticleId IdType="pmc">PMC4213316</ArticleId><ArticleId IdType="pubmed">24519258</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S, Guo X, Yu S, Yang H, Sun G, Li Z, et al. Hypertriglyceridemic waist phenotype and metabolic abnormalities in hypertensive adults: A STROBE compliant study. Medicine (Baltimore) 2016;95(49):e5613. doi: 10.1097/MD.0000000000005613.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000005613</ArticleId><ArticleId IdType="pmc">PMC5266061</ArticleId><ArticleId IdType="pubmed">27930589</ArticleId></ArticleIdList></Reference><Reference><Citation>Nita C, Hancu N, Rusu A, Bala C, Roman G. Hypertensive waist: first step of the screening for metabolic syndrome. Metab Syndr Relat Disord. 2009;7:105&#x2013;110. doi: 10.1089/met.2008.0039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/met.2008.0039</ArticleId><ArticleId IdType="pubmed">19032044</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabrera-Rode E, Borja Coronel AC, Montes de Oca-Somoano R, Rodr&#xed;guez-Acosta J, Cubas-Due&#xf1;as I, Arnold-Dom&#xed;nguez Y, et al.  Utilidad del fenotipo hipertensi&#xf3;n-obesidad abdominal para identificar personas con s&#xed;ndrome metab&#xf3;lico.  [2022 Mayo 14];Revista ALAD. 2020 10(4) Disponible en:  https://bit.ly/42Vp6VS
.</Citation></Reference><Reference><Citation>Parl&#xe1;-Sardi&#xf1;as J, Cabrera-Rode E, Rodr&#xed;guez-Acosta J, Cubas-Due&#xf1;as I, Arnold-Dom&#xed;nguez Y, Hern&#xe1;ndez-Rodr&#xed;guez J, et al.  Utilidad del fenotipo hipertensi&#xf3;n-obesidad abdominal para identificar personas con riesgo cardiovascular global moderado y alto.  [2022 Mayo 14];Rev Cubana Endocrinol. 2020 31(3):e248.  Disponible en:  https://bit.ly/3STtH6f
.</Citation></Reference><Reference><Citation>Cheng YH, Tsao YC, Tzeng IS, Chuang HH, Li WC, Tung TH, et al. Body mass index and waist circumference are better predictors of insulin resistance than total body fat percentage in middle-aged and elderly Taiwanese. Medicine (Baltimore) 2017;96(39):e8126. doi: 10.1097/MD.0000000000008126.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000008126</ArticleId><ArticleId IdType="pmc">PMC5626286</ArticleId><ArticleId IdType="pubmed">28953643</ArticleId></ArticleIdList></Reference><Reference><Citation>Darsini D, Hamidah H, Notobroto HB, Cahyono EA. Health risks associated with high waist circumference: A systematic review. J Public Health Res. 2020;9(2):1811&#x2013;1811. doi: 10.4081/jphr.2020.1811.</Citation><ArticleIdList><ArticleId IdType="doi">10.4081/jphr.2020.1811</ArticleId><ArticleId IdType="pmc">PMC7376462</ArticleId><ArticleId IdType="pubmed">32728557</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#xed;az O, Hern&#xe1;ndez J, Dom&#xed;nguez E, Mart&#xed;nez I, Bosch Y, del Busto A, et al.  Valor de corte de la circunferencia de la cintura como predictor de disglucemia.  [2022 Mayo 14];Rev Cubana Endocrinol. 2017 28(1) Internet. 
 https://bit.ly/42TyHfI
.</Citation></Reference><Reference><Citation>Hu FB, Stampfer MJ. Insulin resistance and hypertension: the chic-ken-egg question revisited. [2023 Ago 24];Circulation. 2005 112(12):1678&#x2013;1680. doi: 10.1161/CIRCULATIONAHA.105.568055. Internet. Disponible en:</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.105.568055</ArticleId><ArticleId IdType="pubmed">16172279</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang T, Zhang H, Li S, Li Y, Liu Y, Fernandez C, et al. Impact of adiposity on incident hypertension is modified by insulin resistance in adults: Longitudinal observation from the Bogalusa Heart Study. Hypertension. 2016;67(1):56&#x2013;62. doi: 10.1161/HYPERTENSIONAHA.115.06509.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.115.06509</ArticleId><ArticleId IdType="pmc">PMC4679582</ArticleId><ArticleId IdType="pubmed">26573703</ArticleId></ArticleIdList></Reference><Reference><Citation>Ministerio de Salud P&#xfa;blica. Direcci&#xf3;n nacional de estad&#xed;sticas y registros m&#xe9;dicos  . Anuario estad&#xed;stico de salud 2021. La Habana: Ministerio de Salud P&#xfa;blica; 2022.  [2023 Jun 16].  Disponible en:  https://bit.ly/3Tf9KZ2
.</Citation></Reference><Reference><Citation>Bonet M, Varona P, Chang M, Garc&#xed;a RG, Suarez R, Arc&#xed;a N, et al.   III Encuesta nacional de factores de riesgo y actividades preventivas de enfermedades no trasmisibles. Cuba 2010-2011. 2014.  [2022 Mayo 14].  Internet. Disponible en:  https://bit.ly/48wyYXs
.</Citation></Reference><Reference><Citation>D&#xed;az-S&#xe1;nchez ME, Maldonado G, Su&#xe1;rez-Medina R, Varona P.  Nuevos datos sobre el sobrepeso y la obesidad en Cuba. 2022.  [2023 Jun 15].  Disponible en:  https://bit.ly/3SN7CWU
.</Citation></Reference><Reference><Citation>Ministerio de Salud P&#xfa;blica. Direcci&#xf3;n nacional de estad&#xed;sticas y registros m&#xe9;dicos . Anuario estad&#xed;stico de salud 2020. La Habana: Ministerio de Salud P&#xfa;blica; 2021. [2023 Jun 16]. Internet.</Citation></Reference><Reference><Citation>Ortega MA, Fraile-Mart&#xed;nez O, Naya I, Garc&#xed;a-Honduvilla N, &#xc1;lvarez-Mon M, Buj&#xe1;n J, et al. Type 2 diabetes mellitus associated with obesity (diabesity). The central role of gut microbiota and its translational applications. Nutrients. 2020;12(9):2749&#x2013;2749. doi: 10.3390/nu12092749.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu12092749</ArticleId><ArticleId IdType="pmc">PMC7551493</ArticleId><ArticleId IdType="pubmed">32917030</ArticleId></ArticleIdList></Reference><Reference><Citation>ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, et al. American Diabetes Association. 2. Classification and diagnosis of diabetes: standards of care in Diabetes-2023. Diab Care. 2023;46(1):S19&#x2013;S40. doi: 10.2337/dc23-S002.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc23-S002</ArticleId><ArticleId IdType="pmc">PMC9810477</ArticleId><ArticleId IdType="pubmed">36507649</ArticleId></ArticleIdList></Reference><Reference><Citation>helton PK, Carey RM, Aronow WS, Casey DE, Jr, Collins KJ, Dennison-Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: Executive summary: A report of the American college of cardiology/American heart association task force on clinical practice guidelines. Hypertension. 2018;71(6):1269&#x2013;1324. doi: 10.1161/HYP.0000000000000066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYP.0000000000000066</ArticleId><ArticleId IdType="pubmed">29133354</ArticleId></ArticleIdList></Reference><Reference><Citation>Arranz-Calzado C, Gonz&#xe1;lez-Su&#xe1;rez RM, &#xc1;lvarez-&#xc1;lvarez A, Rodr&#xed;guez-Pend&#xe1;s B, Reyes-Dur&#xe1;n A. Criterios de referencia para los indicadores de secreci&#xf3;n de insulina y de los par&#xe1;metros lip&#xed;dicos en una poblaci&#xf3;n mixta hospitalaria.  [2022 Mayo 14];Rev Cubana Endocrinol. 2010 21(1):1&#x2013;12. Internet. Disponible en:  https://bit.ly/49vrlSb
.</Citation></Reference><Reference><Citation>Inoue Y, Qin B, Poti J, Sokol R, Gordon-Larsen P. Epidemiology of obesity in adults: Latest trends. Curr Obes Rep. 2018;7(4):276&#x2013;288. doi: 10.1007/s13679-018-0317-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13679-018-0317-8</ArticleId><ArticleId IdType="pmc">PMC6215729</ArticleId><ArticleId IdType="pubmed">30155850</ArticleId></ArticleIdList></Reference><Reference><Citation>Qing L, Wei R, Chan L, Xiaoya Z, Xin X. Sensitivity of various body indices and visceral adiposity index in predicting metabolic syndrome among Chinese patients with adult growth hormone deficiency. J Endocrinol Invest. 2017;40(6):653&#x2013;661. doi: 10.1007/s40618-017-0621-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40618-017-0621-2</ArticleId><ArticleId IdType="pmc">PMC5443877</ArticleId><ArticleId IdType="pubmed">28233232</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng J, Lawrence WR, Yang J, Tian J, Li C, Lian W, et al. Association between serum uric acid and obesity in Chinese adults: a 9-year longitudinal data analysis. BMJ Open. 2021;11(2):e041919. doi: 10.1136/bmjopen-2020-041919.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2020-041919</ArticleId><ArticleId IdType="pmc">PMC7908911</ArticleId><ArticleId IdType="pubmed">33550245</ArticleId></ArticleIdList></Reference><Reference><Citation>Delgado-Acosta H, Lastre-Navarro K, Vald&#xe9;s-G&#xf3;mez M, Benet-Rodr&#xed;guez M, Morej&#xf3;n-Giraldoni AF, Zerquera-Rodr&#xed;guez J. Prevalencia de hipertensi&#xf3;n arterial en el &#xc1;rea I del municipio Cienfuegos. Segunda medici&#xf3;n de la iniciativa CARMEN: cifras alarmantes.  [2022 Mayo 14];Rev Finlay. 2015 5(1):4&#x2013;11. Internet. Disponible en:  https://bit.ly/49QVNGo
.</Citation></Reference><Reference><Citation>Miguel-Soca PE, Rivas-Est&#xe9;vez M, Sarmiento-Teruel Y, Mari&#xf1;o-Soler AL, Marrero-Hidalgo M, Mosqueda-Batista L, et al. Prevalence of metabolic syndrome risk factors in adults in Holgu&#xed;n, Cuba (2004-2013) MEDICC Rev. 2016;18(1-2):28&#x2013;28. doi: 10.37757/MR2020.V22.N3.3.</Citation><ArticleIdList><ArticleId IdType="doi">10.37757/MR2020.V22.N3.3</ArticleId><ArticleId IdType="pubmed">34362239</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong-McClure RA, Gregg EW, Barcel&#xf3; A, Lee K, Abarca-G&#xf3;mez L, Sanabria-L&#xf3;pez L, et al.  Prevalence of metabolic syndrome in Central America: a cross-sectional population-based study.  [2022 Mayo 14];Rev Panam Salud Publica. 2015 38(3):202&#x2013;208. Internet. Disponible en:  https://bit.ly/42Y8wow
.</Citation><ArticleIdList><ArticleId IdType="pubmed">26757998</ArticleId></ArticleIdList></Reference><Reference><Citation>Ord&#xfa;&#xf1;ez P, Kaufman JS, Benet M, Morejon A, Silva LC, Shoham DA, et al. Blacks and whites in the Cuba have equal prevalence of hypertension: confirmation from a new population survey. BMC Public Health. 2013;13(1):169&#x2013;169. doi: 10.1186/1471-2458-13-169.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2458-13-169</ArticleId><ArticleId IdType="pmc">PMC3635894</ArticleId><ArticleId IdType="pubmed">23433343</ArticleId></ArticleIdList></Reference><Reference><Citation>Montoya Rodr&#xed;guez MA.  Acantosis nigricans como factor asociado a hipertensi&#xf3;n arterial en pacientes del Hospital Bel&#xe9;n de Trujillo. Universidad Privada Antenor Orrego-UPAO; 2020.  [2023 Ago 24].  Internet. Disponible en:  https://bit.ly/3OUJWPy
.</Citation></Reference><Reference><Citation>Da Silva AA, do Carmo JM, Li X, Wang Z, Mouton AJ, Hall JE. Role of hyperinsulinemia and insulin resistance in hypertension: Metabolic syndrome revisited. Can J Cardiol. 2020;36(5):671&#x2013;682. doi: 10.1016/j.cjca.2020.02.066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cjca.2020.02.066</ArticleId><ArticleId IdType="pmc">PMC7219403</ArticleId><ArticleId IdType="pubmed">32389340</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancusi C, Izzo R, di Gioia G, Losi MA, Barbato E, Morisco C. Insulin resistance the hinge between hypertension and type 2 diabetes. High Blood Press Cardiovasc Prev. 2020;27(6):515&#x2013;526. doi: 10.1007/s40292-020-00408-8. Internet.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40292-020-00408-8</ArticleId><ArticleId IdType="pmc">PMC7661395</ArticleId><ArticleId IdType="pubmed">32964344</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>